Brief: FDA Approves Expanded Indication For Avtozma® Intravenous Formulation In Cytokine Release Syndrome
06/08/2025 13:41
Aug 6 (Reuters) - Celltrion Inc 068270.KS: FDA APPROVES EXPANDED INDICATION FOR AVTOZMA® (TOCILIZUMAB-ANOH) INTRAVENOUS (IV) FORMULATION IN CYTOKINE RELEASE SYNDROME (CRS) Source text: ID:nPn8MVwVqa Further company coverage: 068270.KS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares